Abstract:Purpose: The aim of this study was to develop cilostazol (CLT) nanocrystals intended to improve its dissolution rate and enhance its bioavailability. Methods: In this study, CLT nanosuspension was prepared by the anti-solvent and high-pressure homogenization method. The effects of the production parameters, such as the stabilizer concentration, pressure and number of cycles, were investigated. Then the CLT nanosuspensions were sprayed to dry powders. Characterization of the product was performed by scanning electron microscopy (SEM), Nitrogen adsorption, differential scanning calorimetry (DSC), X-ray powder diffraction analysis (XRPD), X-ray Photoelectron Spectroscopy (XPS), particle size analysis and dissolution testing. Additionally, the comparison studies of oral relative bioavailability in beagle dogs of two type tables were performed. Results: The images of SEM showed a spherical smooth CLT powder, and Nitrogen adsorption test revealed spray dried powder were porous with high BET surface area compared with that of raw CLT. DSC and XRPD results demonstrated that the combination of preferred polymorph B and C of CLT were prepared successfully, the saturation solubility of the nanosized crystalline powder is about 5 fold greater than that of raw CLT, and the dissolution rate was enhanced 4 fold than that of raw CLT. The Cmax and AUC(0-48h) of CLT nanosized crystalline tablets were 2.1 fold and 1.9 fold, and 3.0 fold and 2.3 fold compared with those of the nanosized tablets and commercial tablets, respectively. Conclusion: The anti-solvent-high-pressure homogenization technique was employed successfully to produce cilostazol nanosuspensions. The bioavailability of CLT tablets prepared using spray dried nanosized crystalline powder after oral administration to dogs was markedly increased compared with that produced by nanosized tablets and commercial tablets, because of its greater dissolution rate owing to its transition of the crystalline state to form C and form B, reduced particle size and porous structure with increased surface area.

Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.

A Wet-Milling Method for the Preparation of Cilnidipine Nanosuspension with Enhanced Dissolution and Oral Bioavailability

Preparation and evaluation of celecoxib nanosuspensions for bioavailability enhancement

Preparation and optimization of surface stabilized cryptotanshinone nanocrystals with enhanced bioavailability

Role of Surfactant Micellization for Enhanced Dissolution of Poorly Water-Soluble Cilostazol Using Poloxamer 407-Based Solid Dispersion via the Anti-Solvent Method

The Increased Dissolution and Oral Absorption of Itraconazole by Nanocrystals with an Endogenous Small-Molecule Surfactant as a Stabilizer

Physical and dissolution characterization of cilostazol solid dispersions prepared by hot melt granulation (HMG) and thermal adhesion granulation (TAG) methods

Preparation of Loratadine Nanocrystal Tablets to Improve the Solubility and Dissolution for Enhanced Oral Bioavailability

Preparation, Characterization and Pharmacokinetics of Cyadox Nanosuspension

Enhancement of dissolution and oral bioavailability by adjusting microenvironment pH in crocetin ternary solid dispersions: Optimization, characterization, in vitro evaluation, and pharmacokinetics

Sustained Delivery of a Camptothecin Prodrug-Cz48 by Nanosuspensions with Improved Pharmacokinetics and Enhanced Anticancer Activity

Preparation and in Vitro/In Vivo Evaluation of Fenofibrate Nanocrystals

Optimization of Extended-Release ZL-004 Nanosuspensions for In Vivo Pharmacokinetic Study to Enhance Low Solubility and Compliance

Nanocrystal Suspensions for Enhancing the Oral Absorption of Albendazole

Cationic Curcumin Nanocrystals Liposomes for Improved Oral Bioavailability: Formulation Development, Optimization, In Vitro and In Vivo Evaluation

Lyophilized Nanosuspensions for Oral Bioavailability Improvement of Insoluble Drugs: Preparation, Characterization, and Pharmacokinetic Studies

Comparison of three different types of cilostazol-loaded solid dispersion: Physicochemical characterization and pharmacokinetics in rats

Simultaneous Improvement of Dissolution Behavior and Oral Bioavailability of Antifungal Miconazole via Cocrystal and Salt Formation

Development of novel cilostazol-loaded solid SNEDDS using a SPG membrane emulsification technique: Physicochemical characterization and in vivo evaluation

Potent Dried Drug Nanosuspensions for Oral Bioavailability Enhancement of Poorly Soluble Drugs with Ph-Dependent Solubility

Optimization, characterization and in vitro/vivo evaluation of azilsartan nanocrystals